There has been some further FDA action regarding Belviq which is related to the 2020 Belviq drug recall that was due to an increased risk of cancer. This further FDA action means there will be no Belviq generic drugs after the Belviq drug recall in 2020. This February 26, 2021 Notice item, … More
Main Navigation Menu
➤ Current Drug Injury Lawsuits / Pharmaceutical Litigations
➤ Case Evaluations — Free. Confidential. No Obligation.
➤ Information About Law Offices of Thomas J. Lamb
➤ Questions New Clients Have Asked Us (FAQs)
➤ Patient Resources: Medical Sites and More
➤ Collection of Our “Side Effects” Blog Articles
Please know that you can use our Quick Contact Form to tell us about your case.
Recent News & Case Reports
Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
Since the February 2021 FDA alert about Xeljanz-associated heart problems and possible Xeljanz-related cancers was issued, we have been watching for any related drug safety developments concerning Olumiant and Rinvoq. The reason being there has been some concern that those adverse drug events and … More
New Elmiron Medication Guide Points Out Retinal Pigmentary Eye Problems
The new Elmiron Medication Guide mandated by the FDA Center for Drug Evaluation and Research (CDER) in March 2021 follows and reiterates the June 2020 Elmiron label change that added warning about the pigmentary maculopathy Elmiron side effect. We point out that before the June 2020 Elmiron label … More
Beovu Lawsuits are Filed As Individual Cases; 3 Reasons to Contact Us
We want to clear up some possible confusion. If a patient has vision loss or blindness after getting Beovu injections in their eyes, this person must contact a lawyer or law firm to handle their Beovu case in order to get legal compensation for the Beovu drug injury they have suffered. That is … More
Elmiron Can Double the Risk of Pigmentary Maculopathy or Macular Degeneration
Elmiron (pentosan polysulfate sodium, or PPS) was approved by the FDA way back in September 1996 for the treatment of painful bladder syndrome (interstitial cystitis). Over the past several years, however, cases of Elmiron-related eye damage have been reported. Remarkably, according to a recent … More
New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
After the January 2021 release of limited data from a Xeljanz safety trial which often goes by its short name, ORAL Surveillance, some experts raised the possibility that there may consequences for other drugs in the Janus kinase (JAK) inhibitors class of drugs. Specifically, some have asked whether … More